Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
Conditions
Brief summary
The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Detailed description
Kaposiform hemangioendothelioma (KHE) and tufted angiomas (TA) are rare vascular tumors, which are apparent predominantly in infancy or early childhood. Currently, no standard treatment regimens exist for KHE/TA. The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Interventions
DRUGTacrolimus ointment
topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Sponsors
West China Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Exclusion criteria
* Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| reduction in the size of the lesion | 2.5 years | Therapeutic effect is evaluated by reduction in the size of the tumor measured by centimeters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Adverse events | 2.5 years | using the measurement of ratio to evaluate the rate of adverse events of topical application of tacrolimus (such as ratio of Acne vulgaris, pruritis and rash etc.). |
Countries
China
Contacts
Primary ContactYi Ji, PHD, MD
Outcome results
None listed